|Bid||1.3200 x 900|
|Ask||1.4000 x 1200|
|Day's range||1.2000 - 1.4200|
|52-week range||1.1300 - 7.1220|
|Beta (5Y monthly)||0.16|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.00|
BURLINGTON, Mass., March 23, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer, has been invited to present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30, 2022. A pre-recorded presentation will be available for 72 hours beginning Monday, March 28th at 9:00 a.m. Eastern time. Interested p
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
BURLINGTON, Mass., March 07, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM). MTF Biologics is a global nonprofit organization that provides one of the orthopedic industry’s largest portfolios of allograft tissue.